Program
Dexamethasone
Also written as “dexamethasone”, “OTO-104” and “Dexycu”.
Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 200 open or running | phase 3since Mar 6, 2003 | Mar 6, 2003 | none ahead |
| Ocular Therapeutix | 100 open or running | phase 3since Jan 9, 2014 | Jan 9, 2014 | none ahead |
| Takeda | 100 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oculis | 50 open or running | phase 3since Sep 2, 2021 | Oct 16, 2019 | none ahead |
| Sun Pharmaceutical Industries | 50 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Oncotherapeutics | 40 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| eyepoint-pharmaceuticals-inc | 30 open or running | phase 4since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medical | 32 open or running | phase 3since Nov 30, 2020 | Jan 12, 2010 | none ahead |
| Sanofi | 33 open or running | phase 2since Oct 20, 2020 | Oct 20, 2020 | Apr 1, 2027phase 2 · NCT06356571 |
| Alcon | 20 open or running | phase 4since Feb 29, 2008 | Feb 29, 2008 | none ahead |
| Azidus Brasil | 20 open or running | phase 3since Apr 8, 2010 | Apr 8, 2010 | none ahead |
| idrop-inc | 20 open or running | phase 2since Sep 26, 2018 | Sep 26, 2018 | none ahead |
| Merck | 20 open or running | phase 4since May 27, 2008 | Mar 17, 2008 | none ahead |
| ntc-srl | 20 open or running | phase 3since Nov 9, 2018 | Nov 6, 2018 | none ahead |
| ocumension-therapeutics-shanghai-co-ltd | 20 open or running | phase 4since Jun 20, 2024 | May 11, 2024 | none ahead |
| quince-therapeutics-s-p-a | 20 open or running | phase 3since Jan 5, 2011 | Dec 3, 2010 | none ahead |
| sanwa-kagaku-kenkyusho-co-ltd | 20 open or running | phase 2since Mar 27, 2006 | Mar 27, 2006 | none ahead |
| ascension-health | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| Aurobindo Pharma | 10 open or running | phase 2since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| bunker-industria-farmaceutica-ltda | 10 open or running | phase 3since Jul 22, 2009 | Jul 22, 2009 | none ahead |
| clinical-service-china | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
| Cochlear | 11 open or running | no phasesince Sep 12, 2024 | Sep 12, 2024 | none ahead |
| criterium-inc | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| enceladus-pharmaceuticals-bv | 10 open or running | phase 2since Jan 3, 2017 | Jan 3, 2017 | none ahead |
| icon-bioscience-inc | 10 open or running | phase 3since Sep 9, 2015 | Sep 9, 2015 | none ahead |
| Laboratorios Sophia S.A de C.V. | 11 open or running | phase 3since Jul 30, 2025 | Jul 30, 2025 | none ahead |
| Par Health | 10 open or running | phase 3since Jul 25, 2013 | Jul 25, 2013 | none ahead |
| research-insight-llc | 10 open or running | phase 4since Apr 2, 2021 | Apr 2, 2021 | none ahead |
| Simcere Pharmaceutical Group | 10 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| travanti-pharma-inc | 10 open or running | phase 1since May 6, 2009 | May 6, 2009 | none ahead |
Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, onyx-therapeutics-inc, Abbott, tigermed-consulting-co-ltd, accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, novum-pharmaceutical-research-services, tibotec-therapeutics-a-division-of-ortho-biotech-products-l- and prologue-research-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 5, 2011.
- Jun 1, 2021Early phase 1 study in HealthyOcular Therapeutix · NCT04945824 · 2 enrolled · United States
- Sep 2, 2021Phase 3 study in Diabetic Macular EdemaOculis · NCT05066997 · 552 enrolled · United States, Hong Kong, India and more
- Nov 24, 2021Phase 3 study in Inflammation Eye PainOculis · NCT05147233 · 241 enrolled · United States
- Dec 13, 2021eyepoint-pharmaceuticals-inc's first study: phase 4 study in CataractNew to eyepoint-pharmaceuticals-inceyepoint-pharmaceuticals-inc · NCT05191706 · 17 enrolled · United States
- Sep 16, 20222 phase 3 studies in Cataracteyepoint-pharmaceuticals-inc · NCT05550363, NCT05550350
- Jan 20, 2023Phase 2 study in Multiple MyelomaSanofi · NCT05704049 · 118 enrolled · Australia, Brazil, China and more
- Nov 7, 2023Phase 3 study in Inflammation Eye PainOculis · NCT06128369 · 117 enrolled · United States
- Dec 7, 2023Phase 3 study in Diabetic Macular EdemaOculis · NCT06172257 · 401 enrolled · United States, Argentina, India and more
- Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571 · 64 enrolled · United States
- May 11, 2024ocumension-therapeutics-shanghai-co-ltd's first study: phase 3 study in InflammationNew to ocumension-therapeutics-shanghai-co-ltdocumension-therapeutics-shanghai-co-ltd · NCT06429306 · 285 enrolled · China
- Jun 20, 2024Phase 4 study in Inflammationocumension-therapeutics-shanghai-co-ltd · NCT06497699 · 263 enrolled · China
- Sep 12, 2024Cochlear's first study: no phase study in Hearing LossNew to CochlearCochlear · NCT06598059 · 56 enrolled · United States
- Jul 30, 2025Laboratorios Sophia S.A de C.V.'s first study: phase 3 study in Cataract ExtractionNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico
- Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT06356571
- Sep 13, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractorySanofi · NCT04643002
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
The newest 60 of 92 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07305987Cataract Extraction · Mexico | 3 | Recruiting | Laboratorios Sophia S.A de C.V. | Jun 30, 2026 | 134 |
| NCT06598059Hearing Loss · United States | – | Active, not recruiting | Cochlear | Feb 2, 2026 | 56 |
| NCT06497699Inflammation · China | 4 | Completed | ocumension-therapeutics-shanghai-co-ltd | Jul 8, 2023 | 263 |
| NCT06429306Inflammation · China | 3 | Completed | ocumension-therapeutics-shanghai-co-ltd | Nov 24, 2023 | 285 |
| NCT06356571Plasma Cell Myeloma Refractory · United States | 2 | Active, not recruiting | Sanofi | Apr 1, 2027 | 64 |
| NCT06172257Diabetic Macular Edema · United States, Argentina, India and more | 3 | Completed | Oculis | Apr 2, 2026 | 401 |
| NCT06128369Inflammation Eye Pain · United States | 3 | Terminated | Oculis | May 2, 2024 | 117 |
| NCT05704049Multiple Myeloma · Australia, Brazil, China and more | 2 | Active, not recruiting | Sanofi | Dec 22, 2025 | 118 |
| NCT05550363Cataract | 3 | Withdrawn | eyepoint-pharmaceuticals-inc | Sep 2023 | 0 |
| NCT05550350Cataract | 3 | Withdrawn | eyepoint-pharmaceuticals-inc | Sep 2023 | 0 |
| NCT05191706Cataract · United States | 4 | Terminated | eyepoint-pharmaceuticals-inc | Aug 22, 2025 | 17 |
| NCT05147233Inflammation Eye Pain · United States | 3 | Completed | Oculis | Jun 22, 2023 | 241 |
| NCT05066997Diabetic Macular Edema · United States, Hong Kong, India and more | 3 | Completed | Oculis | Apr 10, 2026 | 552 |
| NCT04945824Healthy · United States | Early 1 | Terminated | Ocular Therapeutix | Nov 1, 2022 | 2 |
| NCT04911361Dry Eye Syndromes · United States | 4 | Completed | research-insight-llc | Dec 28, 2021 | 50 |
| NCT04654507Glomerulonephritis · Qatar | 3 | Recruiting | Hamad Medical | Dec 2023 | 120 |
| NCT04643002Plasma Cell Myeloma Refractory · United States, Australia, France and more | 2 | Recruiting | Sanofi | Sep 13, 2027 | 258 |
| NCT04711213Cataract in Inflammatory Ocular Disorders · El Salvador | 2 | Completed | idrop-inc | Oct 31, 2020 | 60 |
| NCT04539548Cataract · United States | 3 | Completed | Ocular Therapeutix | Dec 21, 2023 | 65 |
| NCT04130802Keratitis · United States | 2 | Completed | Oculis | Jan 31, 2020 | 153 |
| NCT04050865Conjunctivitis, Allergic · United States | 3 | Completed | Ocular Therapeutix | Feb 28, 2020 | 96 |
| NCT03739528Cataract · Italy | 3 | Completed | ntc-srl | Dec 19, 2018 | 808 |
| NCT03740659Cataract · Italy | 2 | Completed | ntc-srl | Dec 6, 2018 | 125 |
| NCT03687931Endophthalmitis · United States | 2 | Completed | idrop-inc | Feb 28, 2019 | 60 |
| NCT03646916Diabetes Mellitus · United States | 4 | Withdrawn | ascension-health | Dec 31, 2020 | 0 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03608501Multiple Myeloma · Brazil | 2 | Withdrawn | Takeda | Jun 30, 2021 | 0 |
| NCT03523221Anaphylaxis · Qatar | 1 | Recruiting | Hamad Medical | Dec 2024 | 210 |
| NCT03439293Multiple Myeloma · United States, Czechia, France and more | 2 | Completed | Takeda | Jan 1, 2022 | 61 |
| NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan | 4 | Completed | Takeda | May 28, 2021 | 45 |
| NCT03192150Inflammation · United States | 3 | Completed | Sun Pharmaceutical Industries | Nov 18, 2019 | 246 |
| NCT03192137Inflammation · United States | 3 | Completed | Sun Pharmaceutical Industries | Apr 17, 2019 | 260 |
| NCT03173092Multiple Myeloma · United States | 4 | Terminated | Takeda | Mar 30, 2026 | 141 |
| NCT03104270Multiple Myeloma · United States | 2 | Terminated | Oncotherapeutics | Oct 25, 2019 | 13 |
| NCT03033316Multiple Myeloma | 2 | Terminated | enceladus-pharmaceuticals-bv | Aug 2020 | 7 |
| NCT02988882Chronic Allergic Conjunctivitis | 3 | Completed | Ocular Therapeutix | Apr 27, 2016 | 86 |
| NCT02916420Multiple Myeloma · China | 3 | UNKNOWN | Simcere Pharmaceutical Group | Jun 2018 | 73 |
| NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan | 2 | Completed | Takeda | Aug 31, 2019 | 34 |
| NCT02736175Post-Surgical Ocular Pain | 3 | Completed | Ocular Therapeutix | May 2016 | 438 |
| NCT02547623Cataract · United States | 3 | Completed | icon-bioscience-inc | Aug 16, 2016 | 194 |
| NCT02468700Dry Eye Syndromes | 2 | Completed | Ocular Therapeutix | Aug 2015 | 43 |
| NCT02445326Chronic Allergic Conjunctivitis | 3 | Completed | Ocular Therapeutix | Aug 2015 | 73 |
| NCT02348528Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Sep 29, 2016 | 65 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02089113Post-Surgical Ocular Pain | 3 | Completed | Ocular Therapeutix | Jan 2015 | 241 |
| NCT02062905Chronic Allergic Conjunctivitis | 2 | Completed | Ocular Therapeutix | Aug 2014 | 68 |
| NCT02034019Pain · United States | 3 | Completed | Ocular Therapeutix | Dec 2014 | 247 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Bristol-Myers Squibb | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 2014 | 36 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Bristol-Myers Squibb | Apr 30, 2025 | 186 |
| NCT01910155Otitis Externa · United States, Puerto Rico | 3 | Terminated | Par Health | Feb 2015 | 455 |
| NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more | 3 | Terminated | Bristol-Myers Squibb | Jun 25, 2020 | 23 |
| NCT01792102Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Dec 2018 | 38 |
| NCT01698801Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 26, 2013 | 26 |
| NCT01660750Multiple Myeloma · United States | 1 | Completed | criterium-inc | Aug 2015 | 29 |
| NCT01593410Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Jan 3, 2013 | 194 |
| NCT01575925Multiple Myeloma · United States, Canada | 1 | Completed | Bristol-Myers Squibb | Aug 7, 2018 | 25 |
| NCT01543490Motor Activity · United States | 3 | Completed | Sun Pharmaceutical Industries | Feb 4, 2020 | 558 |
| NCT01328236Leukemia, Plasma Cell · China | 2 | UNKNOWN | clinical-service-china | Sep 2013 | 20 |
| NCT01277289Crohn Disease · Italy, Romania, Spain | 3 | Terminated | quince-therapeutics-s-p-a | Dec 30, 2011 | 51 |
How it is read
Names in the registry
- “Dexamethasone”, 94 entries
- “dexamethasone”, 20 entries
- “OTO-104”, 9 entries
- “Dexycu”, 4 entries
- “Dexamethasone Oral”, 3 entries
Codes read as this program: OCS01.
Conditions, from the studies’ own filings
- Multiple Myeloma, 87 studies
- Cataract, 13 studies
- Macular Edema, 12 studies
- Meniere Disease, 8 studies
- Conjunctivitis, Allergic, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.